

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version 5.1      Revision Date: 09/26/2023      SDS Number: 22987-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/17/2014

### SECTION 1. IDENTIFICATION

Product name : Montelukast Granules Formulation  
Other means of identification : No data available

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 1-551-430-6000  
Emergency telephone : 1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

#### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Montelukast	No data available	151767-02-1	$\geq 0.1 - < 1$ *

\* Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces)

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version 5.1      Revision Date: 09/26/2023      SDS Number: 22987-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/17/2014

with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Montelukast	151767-02-1	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

### Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



ORGANON

## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition	:	No hazardous decomposition products are known.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

products

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Montelukast:

Species : Rabbit  
Result : Mild skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Montelukast:

Species : Rabbit  
Result : Severe irritation

#### Respiratory or skin sensitization

##### Skin sensitization

Not classified based on available information.

##### Respiratory sensitization

Not classified based on available information.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

### Components:

#### Montelukast:

Remarks : No data available

#### Germ cell mutagenicity

Not classified based on available information.

### Product:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster fibroblasts  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

### Components:

#### Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster fibroblasts  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version 5.1      Revision Date: 09/26/2023      SDS Number: 22987-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/17/2014

---

### **Carcinogenicity**

Not classified based on available information.

#### **Product:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Dose : 200 mg/kg body weight  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 92 weeks  
Dose : 100 mg/kg body weight  
Result : negative

#### **Components:**

##### **Montelukast:**

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Mouse  
Application Route : Oral  
Exposure time : 92 weeks  
Result : negative

### **Reproductive toxicity**

Not classified based on available information.

#### **Product:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL Parent: 800 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL Parent: 200 mg/kg body weight  
Symptoms: Reduced fertility

#### **Components:**

##### **Montelukast:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

Fertility: NOAEL: 800 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL: 200 mg/kg body weight  
Symptoms: Reduced fertility

Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: NOAEL: 100 mg/kg body weight  
Symptoms: Reduced fertility

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### Montelukast:

Species : Monkey, male and female  
NOAEL : 150 - 300 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Product:

Skin contact : Remarks: May irritate skin.  
Eye contact : Symptoms: Severe irritation  
Ingestion : Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version 5.1      Revision Date: 09/26/2023      SDS Number: 22987-00022      Date of last issue: 03/20/2023  
Date of first issue: 10/17/2014

### Components:

#### **Montelukast:**

Skin contact : Remarks: May irritate skin.  
Eye contact : Symptoms: Severe irritation  
Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,  
Headache, Cough, Abdominal pain, Diarrhea, Fever

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

#### Components:

#### **Montelukast:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l  
aquatic invertebrates : Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic : NOEC (Pseudokirchneriella subcapitata (green algae)): 100  
plants : mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100  
mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox- : NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l  
icity) : Exposure time: 32 d  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility.

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816  
mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : NOEC (Daphnia magna (Water flea)): 0.23 mg/l  
aquatic invertebrates (Chron- : Exposure time: 21 d  
ic toxicity) : Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

### Persistence and degradability

#### Components:

##### Montelukast:

Biodegradability : Result: not rapidly degradable  
Biodegradation: 0 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

### Bioaccumulative potential

#### Components:

##### Montelukast:

Partition coefficient: n- octanol/water : log Pow: > 4.3

##### Mobility in soil

No data available

##### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



ORGANON

## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

### **TDG**

Not regulated as a dangerous good

### **Special precautions for user**

Not applicable

## SECTION 15. REGULATORY INFORMATION

### **The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

## SECTION 16. OTHER INFORMATION

### **Full text of other abbreviations**

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03/20/2023
5.1	09/26/2023	22987-00022	Date of first issue: 10/17/2014

---

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/26/2023  
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8